Investor Alert: BCSC issues warning about Pegasus Pharmaceuticals Group
VANCOUVER, Oct. 15, 2012 /CNW/ - The British Columbia Securities Commission is warning the public about Pegasus Pharmaceuticals Group Inc. (Pegasus) and its associated companies:
- Careseng Cancer Institute Inc.
- Pegasus BioPark (Dalian) Co., Ltd.
Pegasus has been offering Pegasus bonds and debentures through its website (http://pegasusbonds.com) and sales agents. According to the company's website, Pegasus is using the funds raised for cancer therapy clinics, new drug development and to upgrade manufacturing facilities.
The BCSC is concerned that Pegasus is offering these investments when it has not issued a prospectus or registered with the BCSC. Furthermore, BCSC staff have concerns about the returns offered on the Pegasus investments, which are as high as 100% per annum.
The BCSC urges the public to be wary about investing in Pegasus or its associated companies.
The BCSC urges investors, agents, or members of the public who have been approached or have information about Pegasus Pharmaceuticals or any of its associated companies to contact the BCSC inquiries line at 604-899-6854 or 1-800-373-6393 (toll free).
The BCSC is the independent government agency responsible for regulating trading in securities within the province. Learn how to avoid investment fraud at the BCSC's investor education website: www.befraudaware.ca.
SOURCE: British Columbia Securities CommissionFor further information: